How Does GERD Lead to Esophageal Cancer?
GERD results in esophageal cancer via a stepwise process that occurs over years to decades. The repeated injury to the esophagus by acid and bile in the setting of GERD ultimately results in a process called Barrett’s esophagus. In this process, the squamous cells in the esophagus are replaced by intestinal-type columnar cells. The cells in Barrett’s esophagus are more resistant to acid injury than the normal esophageal cells. However, the risk of developing cancer in these cells is significantly higher.
The cells in Barrett’s esophagus can undergo genetic mutations over time. This process of genetic mutation in the cells in Barrett’s esophagus is called dysplasia. In this process, the cells in the esophagus become cancerous. The process of progression from GERD to Barrett’s esophagus to esophageal cancer occurs over years to decades.
What Is the Actual Cancer Risk From GERD?
Understanding the absolute cancer risk from GERD helps contextualize the relationship between acid reflux and esophageal cancer without creating undue anxiety for the majority of GERD patients.
- The risk of esophageal adenocarcinoma in the general GERD population is low, estimated at approximately 1 in 860 GERD patients per year according to a meta-analysis published in Gut (2014)
- Barrett's esophagus without dysplasia carries an annual cancer risk of approximately 0.3 percent
- Low-grade dysplasia carries an annual cancer risk of approximately 0.5 to 1 percent
- High-grade dysplasia carries an annual cancer risk of approximately 5 to 10 percent
- Despite the low absolute risk for individual GERD patients, the population-level burden is significant, given the hundreds of millions of people globally with GERD
The key message is that while most people with GERD will never develop esophageal cancer, the risk is real and increases substantially with certain high-risk features.
Who Is at Highest Risk of Esophageal Cancer From GERD?
Not all GERD patients carry equal cancer risk. Specific factors significantly increase the risk of progression from GERD to esophageal adenocarcinoma:
- Long-standing GERD symptoms lasting more than 5 years
- Male sex: Esophageal adenocarcinoma is six to eight times more common in men than in women
- Age over 50
- Central obesity, particularly excess abdominal fat accumulation
- Smoking both current and former
- Confirmed Barrett's esophagus on endoscopy
- Presence of high-grade dysplasia in Barrett's esophagus
- White ethnicity
- Family history of Barrett's esophagus or esophageal adenocarcinoma
What Are the Symptoms of Esophageal Cancer From GERD?
Early esophageal adenocarcinoma rarely causes noticeable symptoms, which is why endoscopic surveillance in high-risk GERD patients is critical for early detection. When symptoms develop, they typically indicate more advanced disease:
- Progressive difficulty swallowing (dysphagia), initially with solid foods and later with soft foods and liquids
- Unintentional and significant weight loss
- Persistent chest pain or pressure not relieved by PPI therapy
- Vomiting or regurgitation of blood
- Persistent hoarseness or chronic cough from tumor involvement of surrounding structures
- Fatigue and general weakness from anemia caused by tumor bleeding
Any new or worsening swallowing difficulty in a GERD patient, particularly with weight loss, requires urgent endoscopic evaluation to exclude esophageal cancer.
How Can the Risk of Esophageal Cancer From GERD Be Reduced?
Effective GERD Treatment
Management of acid exposure time through PPI therapy is considered the most important factor in controlling cancer risk in GERD patients. According to a study published in Gut (2014), long-term PPI therapy is associated with a significantly reduced risk of progression of dysplasia and cancer in Barrett's esophagus. PPIs reduce acid-induced DNA damage to esophageal cells that drives the mutation pathway toward cancer.
Barrett's Esophagus Screening and Surveillance
Endoscopic screening helps in the early detection of Barrett’s esophagus. In patients with Barrett’s esophagus, surveillance endoscopy helps in the early detection of dysplasia. ACG (2022) suggested the surveillance endoscopy schedule for patients with Barrett’s esophagus:
- No dysplasia: Endoscopy at 3- to 5-year intervals
- Low-grade dysplasia: Endoscopy at 6- to 12-month intervals or endoscopic treatment
- High-grade dysplasia:Endoscopic eradication therapy immediately
Endoscopic Eradication Therapy
Radiofrequency ablation (RFA) is the gold standard treatment for dysplastic Barrett's esophagus. RFA destroys precancerous Barrett's tissue before cancer develops, achieving complete dysplasia eradication in approximately 90 percent of patients according to the NEJM (2009). Endoscopic mucosal resection (EMR) removes visible nodular lesions containing early cancer or high-grade dysplasia.
Weight Loss
Central obesity is known to increase the risk of esophageal cancer. This is because central obesity is associated with an increase in acid reflux, high intra-abdominal pressure, and systemic inflammatory hormones that induce cellular mutations. Weight loss decreases all these cancer risk factors at once.
Smoking Cessation
Smoking independently increases esophageal adenocarcinoma risk beyond its contribution to GERD. Smoking cessation reduces both GERD severity and the direct carcinogenic effects of tobacco smoke on esophageal cells.
Aspirin and NSAIDs
The evidence that is coming up suggests that the regular use of aspirin or NSAIDs may prevent the progress of cancer in the esophagus in Barrett’s esophagus patients. According to the study published in the journal Gastroenterology (2012), regular aspirin use is associated with the prevention of esophageal adenocarcinoma in Barrett’s esophagus. However, the regular use of aspirin in cancer prevention should be under medical supervision due to bleeding risks.
Conclusion
While it is true that GERD and cancer of the esophagus are associated with each other, it is not as if it is set in stone. The vast majority of GERD sufferers will not get cancer of the esophagus. However, in those who have high risk factors for cancer, such as longstanding symptoms, Barrett’s Esophagus, central obesity, and smoking history, successful management of your GERD symptoms with consistent PPI therapy may reduce your risk for cancer. If you have had longstanding symptoms of GERD and have not had an endoscopy, discuss Barrett’s Esophagus screening with your gastroenterologist and develop your cancer risk reduction strategy.
